KVUE Kenvue Inc. Common Stock

Keurig Dr Pepper has hired Russ Torres as chief executive of its coffee spinoff, plucking the executive from Kimberly Clark.

Kimberly-Clark just logged its 54th straight year of dividend increases, but a shrinking raise, falling free cash flow, and a massive acquisition in progress raise a pointed question for income investors living on those checks.

Rising rates have boomers flocking to Treasuries, but five battle-tested dividend payers with 50-plus years of consecutive increases may offer something bonds simply cannot deliver.

Kimberly-Clark has raised its dividend through every recession of the past two decades, but a $48.7 billion acquisition and free cash flow that already fell short of last year's dividend payment put that streak in genuine jeopardy.

Kimberly-Clark hands retirees a fatter dividend check every quarter, but one look at what sits behind that payout changes the picture fast. Before you choose the bigger yield, consider what happens when the income has to last decades.

Kimberly-Clark just logged 54 straight years of dividend raises, but a closer look at the cash flow statement raises an uncomfortable question about who is actually funding that growing payout.

While investors pile into pricey AI darlings, a handful of battle-tested Dividend Kings have quietly slipped to levels that scream value, and Wall Street analysts see serious upside ahead for 2027.

This article first appeared on GuruFocus. Kenvue Inc (NYSE:KVUE) recently announced a total dividend of $0.21 per share, with the ex-dividend date set for 2026-09-21. For income-focused investors, the ex-dividend date is a critical marker: shareholders must own the stock before this date to qualify for the payment.

Kimberly-Clark (NasdaqGS:KMB) plans to sell assets tied to its planned US$40b acquisition of consumer products group Kenvue. The disposals are aimed at addressing European Union antitrust concerns linked to overlaps in consumer health and personal care brands. Asset sale discussions focus on EU markets where regulators flagged competition issues as part of their ongoing review of the Kenvue deal. Kimberly-Clark's move to sell assets around the US$40b Kenvue deal sits within a broader pattern...

Younger investors are rewriting the rules of wealth building, and five overlooked dividend stocks under $20 sit right at the center of that shift. The real question is whether these picks can hold up long enough to matter.

One healthcare dividend payer carries legal risk, the other faces a buyout. Here's which one actually deserves your money.

Kenvue Inc. previously announced that its Board of Directors declared a quarterly dividend of US$0.21 per share, payable on October 2, 2026, to shareholders of record as of September 21, 2026, while also securing FDA approval for TYLENOL with Naproxen, a first-of-its-kind non-opioid OTC pain reliever backed by multiple clinical studies. By pairing a new, clinically supported TYLENOL with Naproxen launch with ongoing cash returns via dividends, Kenvue is highlighting both product innovation...

Kenvue (KVUE) is on investors’ radar after launching TYLENOL with Naproxen, an FDA-approved, opioid-free over the counter pain reliever that combines acetaminophen and naproxen sodium, backed by extensive clinical research. That launch comes as Kenvue’s share price has softened in the short term, with a 7 day share price return of down 4.43% and a 30 day share price return of down 6.72%. Even though the year to date share price return is 3.41% and the 1 year total shareholder return is 2.85%,...

Kimberly-Clark Corporation (NASDAQ:KMB) is preparing asset sales to address EU antitrust concerns surrounding its planned $40 billion acquisition of Kenvue, according to Reuters. The company is reportedly seeking to offer remedies that could secure European Commission approval by the September 29 deadline, avoiding a more extensive four-month investigation. Similar regulatory concerns have already emerged in […]

Consumer stocks were mixed late Monday afternoon, with the State Street Consumer Staples Select Sect

Kenvue's dependable dividend is above average, and it could go even higher if the company is bought by Kimberly-Clark.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.6%, and the actively t

Colgate is reportedly shopping Softsoap, Irish Spring, and Speed Stick with Goldman Sachs running the process, but the names most investors would expect to step up all have reasons to sit this one out.

Kenvue stock has lagged the broader market over the past year, although analysts remain neutral on the company’s future prospects.

Kimberly-Clark just raised its dividend for the 54th straight year while simultaneously chasing a nearly $50 billion acquisition, and income investors are now weighing whether a deal of that size can coexist with a payout that costs over $1.6 billion annually.

KVUE's trusted brands, innovation and productivity initiatives support growth as it strengthens its consumer health portfolio and global reach.

Kimberly-Clark Corporation’s (NASDAQ:KMB) proposed $40 billion takeover of Kenvue has entered another stage of regulatory review. Documents on the European Commission’s website show that Kimberly-Clark has requested EU permission to complete the transaction, which was first announced in November 2025. The deal would combine Kimberly-Clark (NASDAQ:KMB) with a large portfolio of consumer-health brands, including Tylenol, […]

KVUE nears its planned combination after shareholder and U.S. antitrust clearances, while margin, debt and legal risks temper the Q4 2026 outlook.

Kenvue's profit margins and cash flow improved in the first half, but modest sales growth, debt and uneven segment trends keep the risk-reward balanced.

Deal skepticism and litigation fears still weigh on this consumer staples stalwart.

Kimberly-Clark (KMB) stock is in focus after the company named Suzana Blades as Senior Vice President and General Counsel, with a future role tied to its pending acquisition of Kenvue Inc. Kimberly-Clark shares trade at US$110.34, with the stock up 10.2% over the past 90 days and 8.8% year to date on a share price basis, even though the 1 year total shareholder return has declined 11.1%. This points to improving short term momentum alongside a weaker longer term experience for...

Kimberly-Clark stock has declined 11.1% over the past year, yet both its earnings multiples and a Discounted Cash Flow (DCF) intrinsic value estimate currently point to a cheaper valuation than the market price suggests. With the share price near US$110, the key issue for investors is whether this apparent discount fairly reflects the company’s cash generation and risk profile. The 11.1% share price decline over 1 year signals that investors have been cautious on Kimberly-Clark despite a...

The beauty group's repricing rests on a profit plan it controls, while the low end of its new sales guidance is no faster than the year just ended.

Kenvue stock has delivered a 9.3% gain year to date. Its current share price of US$18.93 still sits well below an intrinsic value estimate from a Discounted Cash Flow (DCF) model, which points to a 36.4% discount. At the same time, traditional earnings multiples suggest the shares look about fairly priced, leaving investors weighing a clear DCF upside signal against more neutral market ratios. Year to date, Kenvue is up 9.3%, indicating the market has already repriced the stock higher even...

In August 2026, Kenvue’s Zyrtec brand launched Zyrtec Allergen Shield Spray, a drug-free nasal mist that forms a gel barrier in the nose within minutes to help block common airborne allergens like pollen, pet dander, and dust for up to six hours in adults and children aged 12 and older. This first-of-its-kind, HPMC-based spray expands Zyrtec’s toolkit toward proactive allergen defense, signaling Kenvue’s push into drug-free, preventative allergy solutions. We’ll now examine how this new...

Johnson & Johnson's new drugs may offset declining sales due to patent-protection losses.

Panettiere's death has re-ignited calls to boycott Neutrogena, which she said ended a partnership after she spoke out about postpartum depression.

Zyrtec Allergen Shield Spray, a new drug free nasal mist from Kenvue (KVUE), has given investors fresh product news to weigh. The launch highlights activity in the company’s Self Care allergy portfolio. See our latest analysis for Kenvue. The recent Zyrtec Allergen Shield Spray launch comes after Kenvue reported second quarter 2026 sales of US$3,955 million and net income of US$456 million on August 6, while also completing a US$439.14 million share repurchase program that covered 20,387,000...

Personal care products provider Kimberly-Clark Corporation (NYSE:KMB)’s shares are down by 17% over the past year and are up by 9% year-to-date. It is currently undergoing a major transformation through acquiring Kenvue. Cramer has discussed Kimberly-Clark Corporation (NYSE:KMB)’s acquisition several times and linked its performance with consumer goods giant Procter & Gamble. In his morning […]

KVUE's Q2 sales and earnings miss estimates, but organic growth improved as Skin Health and Beauty led a broader recovery.

Kenvue just snapped a four-quarter earnings streak while Reddit falls nearly silent, and the reason why tells you everything about where this stock goes next.

Sales and earnings increased across Kenvue's portfolio, but tariffs, inflation and currency costs reduced profitability.

Kenvue posts higher Q2 sales and earnings, but both miss estimates as inflation, tariffs and foreign exchange pressure margins.

Kenvue Inc (NYSE:KVUE) shares fell about 2% on Thursday after the consumer health company reported second quarter results that narrowly missed Wall Street expectations, while margins declined from a year earlier. The company reported adjusted diluted earnings per share of $0.31, compared with...

Kenvue (KVUE) delivered earnings and revenue surprises of -3.13% and -0.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

US equity markets were mostly pointing higher before the opening bell Thursday as investors assess p

Kenvue reported higher profit and sales in the second quarter, boosted by higher prices and volumes, as the company continues working to turn around its business ahead of its acquisition by Kimberly-Clark.

Today Economic data: Weekly jobless claims, preliminary productivity and costs report for the second quarter, EIA weekly natural gas storage report, Challenger job-cuts report Earnings (a.m.): ConocoPhillips, Warner Bros Discovery, Kenvue, Fox Corp, Hertz, Keurig Dr Pepper, Datadog, Ralph Lauren Earnings (p.

Kimberly-Clark's (KMB) Q2 earnings beat showed the company can deliver steady profit growth despite

Today Federal Reserve speakers: Fed governor Lisa Cook Economic data: the Energy Information Administration’s weekly petroleum status report, U.S. services PMI, global services PMI, ADP employment survey Earnings (a.

Kimberly-Clark stock has fallen 15.9% over the past year, yet an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach currently points to the shares trading at a sizeable discount to that estimate, while broader checks and earnings multiples suggest something closer to a fair price. The 15.9% share price decline over the last 12 months reflects weaker recent returns, which can matter if the market is reassessing Kimberly-Clark’s prospects. The planned acquisition of...

Today Earnings (a.m.): Merck, Pfizer, McDonald's, Caterpillar, Spotify, Apollo, TPG, Marathon Petroleum, Archer-Daniels-Midland, DuPont, Kimberly-Clark Earnings (p.m.): SpaceX, Advanced Micro Devices, ...

KVUE is expected to post Q2 revenue and earnings growth as brand strength, innovation and productivity efforts offset seasonal and cost pressures.

Church & Dwight (CHD) delivered earnings and revenue surprises of 0.00% and +1.79%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

KVUE's trusted brands, margin gains and pending Kimberly-Clark deal shape its outlook amid mixed growth signals.